Clinical review report: Eculizumab (Soliris) Alexion Pharma Canada Corp. : indication: neuromyelitis optica spectrum disorder
The objective of this report was to perform a systematic review of the beneficial and harmful effects of eculizumab 10 mg/mL intravenous infusion for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, October 2020
|
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of eculizumab 10 mg/mL intravenous infusion for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive |
|---|---|
| Physical Description: | 1 PDF file (105 pages) illustrations |